ICOS and neoplasm: Following pembrolizumab therapy, the TME of responders becomes activated, as evidenced by the increased immune activation gene score, increased frequency of ICOS+ and Ki-67+ CD4+ T cells, and a local enrichment of tumor cells with dendritic cells (CN-5) and CD4+ T cells (CN-8).